文献速递神经免疫

富马酸二甲酯可延缓放射学孤立综合征进展为多发性硬化

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
PubMed 文献 · Ann Neurol · 2022-12-10

这项多中心随机双盲安慰剂对照研究纳入放射学孤立综合征患者,评估口服富马酸二甲酯240mg每日两次能否延缓首次临床脱髓鞘事件。96周内富马酸二甲酯组首次临床事件风险显著低于安慰剂组(HR=0.18,95%CI 0.05-0.63,p=0.007),中度不良事件较安慰剂组多见。

要点

  • 放射学孤立综合征患者口服富马酸二甲酯240mg每日两次,96周内首次临床脱髓鞘事件风险显著降低(HR=0.18)。
  • 富马酸二甲酯组中度不良事件34例(32%),安慰剂组19例(21%);严重事件两组相似。
  • 这是首个证明疾病修正治疗可预防放射学孤立综合征首次急性临床事件的随机临床试验。

核心结论

  • 富马酸二甲酯可降低放射学孤立综合征患者96周内首次临床脱髓鞘事件的风险(HR=0.18,95%CI 0.05-0.63,p=0.007)。
  • 这是首个证明疾病修正治疗在放射学孤立综合征阶段预防首次急性临床事件获益的随机临床试验。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照研究,在美国12个多发性硬化中心开展。
  • 纳入无典型多发性硬化临床症状但脑MRI偶发中枢神经系统脱髓鞘异常者,按1:1随机分配至口服富马酸二甲酯240mg每日两次组(44人)或安慰剂组(43人)。
  • 主要终点为96周随访期内因中枢神经系统脱髓鞘事件出现临床症状的时间,采用意向性分析。
  • 研究注册于ClinicalTrials.gov,编号NCT02739542(ARISE)。
  • 招募时间为2016年3月9日至2019年10月31日。

主要发现

  • 96周研究期内,富马酸二甲酯组首次临床脱髓鞘事件风险在未校正Cox比例风险回归模型中显著低于安慰剂组(HR=0.18,95%CI 0.05-0.63,p=0.007)。
  • 富马酸二甲酯组中度不良事件34例(32%),安慰剂组19例(21%)。
  • 严重不良事件两组相似:富马酸二甲酯组3例(5%),安慰剂组4例(9%)。

临床怎么用

  • 作者认为,这是首个证明疾病修正治疗可预防放射学孤立综合征患者首次急性临床事件的随机临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The radiologically isolated syndrome (RIS) represents the earliest detectable pre-clinical phase of multiple sclerosis (MS). This study evaluated the impact of therapeutic intervention in preventing first symptom manifestation at this stage in the disease spectrum. METHODS: We conducted a multi-center, randomized, double-blinded, placebo-controlled study involving people with RIS. Individuals without clinical symptoms typical of MS but with incidental brain MRI anomalies consistent with central nervous system (CNS) demyelination were included. Within 12 MS centers in the United States, participants were randomly assigned 1:1 to oral dimethyl fumarate (DMF) 240 mg twice daily or placebo. The primary endpoint was the time to onset of clinical symptoms attributable to a CNS demyelinating event within a follow-up period of 96 weeks. An intention-to-treat analysis was applied to all participating individuals in the primary and safety investigations. The study is registered at ClinicalTrials.gov, NCT02739542 (ARISE). RESULTS: Participants from 12 centers were recruited from March 9, 2016, to October 31, 2019, with 44 people randomized to dimethyl fumarate and 43 to placebo. Following DMF treatment, the risk of a first clinical demyelinating event during the 96-week study period was highly reduced in the unadjusted Cox proportional-hazards regression model (hazard ratio [HR] = 0.18, 95% confidence interval [CI] = 0.05-0.63, p = 0.007). More moderate adverse reactions were present in the DMF (34 [32%]) than placebo groups (19 [21%]) but severe events were similar (DMF, 3 [5%]; placebo, 4 [9%]). INTERPRETATION: This is the first randomized clinical trial demonstrating the benefit of a disease-modifying therapy in preventing a first acute clinical event in people with RIS. ANN NEUROL 2023;93:604-614.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Okuda DT, Kantarci O, Lebrun-Frénay C, et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Ann Neurol. 2022. PMID: 36401339. doi:10.1002/ana.26555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。